2. According to the phase I/II clinical trial data of Kangtai Bio-COVID-19 vaccine, the vaccine has no serious adverse reactions above grade 3, and the overall incidence of adverse reactions is not significantly different from that of placebo group, so it is safe.
3. According to the clinical trial data of COVID-19 vaccine published by Kangtai Bio, the expected effective rate of the vaccine is above 90%, and there is no serious adverse reaction above Grade 3. Neutralizing antibody is 2.65 times that of cured patients, ranking first among all COVID-19 vaccine brands in China and fourth in the world.
4. COVID-19 vaccine produced by Kangtai Bio was named KCONVAC. At present, phase III clinical trials have been started. The results of the preliminary phase I/II clinical trial were published on the preprinted website MedRxiv on April 8th, and have not been peer-reviewed.
5. Recently, Shenzhen Kangtai Biological Products Co., Ltd. announced that it had recently received a notice from the research group of the State Council Joint Prevention and Control Mechanism for vaccine research and development. According to the relevant provisions of Article 20 of the Vaccine Management Law of People's Republic of China (PRC), the inactivated novel coronavirus vaccine developed by the company was recommended by the National Health and Wellness Committee and approved for emergency use by the State Pharmaceutical Administration.